Beacon Biosignals upsizes Series B to $97M with $11M extension — Samsung Next and Google Ventures among investors, total $132M
Summary
Beacon Biosignals announced on April 6, 2026 an $11 million extension to its Series B financing, bringing the round to $97 million and cumulative funding to over $132 million. New investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next joined the extension, building on the initial $86M Series B led by Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. CEO Jacob Donoghue said: "This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable." Beacon's Waveband FDA-cleared EEG headband (previously the Dreem 3S) captures real-world neural data during sleep and wakefulness, powering a platform for neurology, psychiatry, and sleep medicine diagnostics, clinical trial analytics, and precision medicine applications. Donoghue described their asset as a "foundation model" of the brain being built from every recorded night of EEG sleep data.
Why it matters
Samsung Next investing in Beacon signals Samsung's strategic interest in brain health data as a complement to their Galaxy wearable ecosystem. Google Ventures' continuing participation through the extension confirms sustained conviction from one of the most selective health tech investors. Beacon at $132M cumulative is now the best-funded pure-play EEG AI company in the world — and Donoghue's "foundation model of the brain" framing positions their growing dataset as the AI-era moat that hardware alone cannot replicate.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial